New BACE1 study launches in the shadow of verubecestat’s demise PM 360, 04 Nov 2017 Generations 2 targets cognitively normal ApoE e4 carriers AT CTAD 2017 BOSTON (FRONTLINE MEDICAL NEWS) – Undeterred by a failed…